In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More participants will probably be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 might be offered as "incorporate-on" therapy. In Section C, https://omarm888dpa1.wikijm.com/user